List of Outstanding Issues, which Radius is addressing with the CHMP. In February 2016 a NDA was filed to the FDA, Radius NDA for abaloparatide-SC was accepted in May, 2016. A Prescription Drug User Fee Act (PDUFA) date was initially granted on March 30, 2016, but then extended to June 30, 2017. As previously stated, abaloparatide injection was approved for use in postmenopausal osteoporosis on April 28, 2017. On 13 October 2022, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Eladynos, intended for the treatment of osteoporosis in postmenopausal women at increased risk of fracture. The applicant for this medicinal product is Radius Health Ireland Ltd. Intellectual Property Radius Health holds three patents on abaloparatide-SC, with expiration dates from 2027 to 2028. The patents relate to the drug composition (US 8148333), and the drug delivery methods (US 7803770 B2 and US 8748382-B2). References External links Osteoporosis drugs Parathyroid hormone receptor agonists